Nonclinical Sciences & Technology

Sept 16

Regulatory shifts ahead: preparing for EU pharmaceutical reform and FDA changes

Register here

 

Sept 16

Overcoming Immunotherapy Resistance in Liver Cancer

  • Mechanisms of immune checkpoint inhibitor resistance
  • PD-L1 regulation and stability in hepatocellular carcinoma
  • Donor-specific variability in immunotherapy response
  • Combination strategies targeting AURKA and PD-L1
  • The PVR/Nectin-2 immune checkpoint pathway
  • NK cell and T cell-mediated
  • Precision immunotherapy for liver cancer

Register here

 

Sept 17

Understanding How the Tumor Microenvironment Reshapes Anti-Tumor Immunity

  • How the tumor microenvironment reshapes infiltrating immune cells
  • In vivo models for tracking immune cell migration and persistence
  • Mechanisms regulating anti-tumor immunity
  • Therapeutic interventions that alter immune cell function
  • Rational development of combination immunotherapies

Register here

 

Sept 18

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Register here

 

Sept 20

Advancing Metabolic Drug Development: Integrated Preclinical Strategies from Discovery to IND-Enabling Studies

Register here

 

Sept 22

Ask The Expert: Navigating the Path From Discovery to Clinical Impact

Register here

 

Sept 29

The Fit-for-Purpose Gap: What RWD Still Gets Wrong

In today's evidence-based healthcare landscape, life sciences companies are surrounded by Real-World Data (RWD). However, having access to massive datasets does not translate to having the right data.

In this session, industry experts Dr. Radek Wasiak and Isabella Even-Chen break down the critical "Fit-for-Purpose Gap"—the misstep of assuming a single, generalized dataset can satisfy every study design, regulatory requirement, or health economics endpoint.

Register here

Oct 7

Rigorous by Design: Strengthening Research That Involves Animals

Register here

------------------------------------------------------------

 

 

---------------------------------------------------------------------------------------------------------------------------------------------------------------------